Resource Type

Journal Article 873

Conference Videos 24

Year

2024 3

2023 60

2022 70

2021 75

2020 53

2019 69

2018 43

2017 53

2016 39

2015 57

2014 47

2013 45

2012 27

2011 35

2010 55

2009 46

2008 30

2007 33

2006 9

2005 4

open ︾

Keywords

fuel cell 13

immunotherapy 8

B-spline 7

large-scale 6

solar cell 6

COVID-19 5

hematopoietic stem cell transplantation 5

hepatocellular carcinoma 5

hydrogen energy 5

stem cell 5

cell proliferation 4

control 4

hepatitis B virus 4

lung cancer 4

microbial fuel cell 4

sensitivity analysis 4

solid oxide fuel cell 4

China 3

chemotherapy 3

open ︾

Search scope:

排序： Display mode:

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellsecond-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuselarge B-cell lymphoma (DLBCL).Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentis a safe and effective therapeutic option for Chinese patients with refractory DLBCL, and further large-scale

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50% long-term complete response in relapsed or refractory diffuse large B-cell lymphoma (DLBCLImmunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansionmetabolism as effective therapeutic strategies to prevent lymphoma relapse in future designs of CAR-Tcell therapy.

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse largeB-cell lymphoma

Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 94-103 doi: 10.1007/s11684-019-0680-1

Abstract:

Autoimmune diseases (ADs) increase the risk of non-Hodgkin’s lymphoma and contribute to poor prognosisto analyze the prognostic value of pretreatment immunologic markers in newly diagnosed patients with diffuselarge B-cell lymphoma (DLBCL).In conclusion, the immunologic status was closely related to lymphoma progression, and this study provides

Keywords： immunologic marker     diffuse large B-cell lymphoma     prognosis    

HTML PDF Collect

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi: 10.1007/s11684-021-0891-0

Abstract: Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL)

Keywords： B-cell lymphoma     oral drug     targeted therapy     immunotherapy     COVID-19 pandemic    

HTML PDF Collect

extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphomaafter chimeric antigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cellimmunotherapy for relapsed or refractory non-Hodgkin lymphoma (r/r NHL) have not been well characterizedIn a cohort of 32 treated patients, 12 (37.5%) and 8 (25%) patients exhibited soft tissue lymphoma andsignificantly and negatively affected OS and PFS in patients with r/r NHL treated with anti-CD19 CAR-T cellThus, anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkinlymphoma    

HTML PDF Collect

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Muhammad Furqan,Yamei Chen,Akintunde Akinleye,Judy Sarungbam,Alan Gass,Karen Seiter,Delong Liu

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 254-258 doi: 10.1007/s11684-014-0319-1

Abstract:

Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma.find a report of myocardial infiltration by this disease since the appraisal of the term “mantle celllymphoma” in 1992.Here we report a case of cardiac involvement by mantle cell leukemia leading to cardiogenic shock which

Keywords： mantle cell lymphoma     bendamustine     cardiogenic shock    

HTML PDF Collect

Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2

Frontiers of Medicine 2023, Volume 17, Issue 3,   Pages 503-517 doi: 10.1007/s11684-022-0947-9

Abstract: Aldolase B (ALDOB), a glycolytic enzyme, is uniformly depleted in clear cell renal cell carcinoma (ccRCCALDOB inhibited CtBP2-mediated repression of multiple cell cycle inhibitor, proapoptotic, and epithelial

Keywords： ALDOB     kidney cancer     cell proliferation    

HTML PDF Collect

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-cellthe causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation

Xiaofeng Shi, Rong Ba, Haiyan You, Qian Jiang, Jiansong Huang, Jianhua Mao, Lanxiu Han, Shuo Zhang, Qin Zhuang, Xianqiu Yu, Lixia Wang, Yun Wang, Dongya Li, Wei Zhu, Yong Zhang, Yan Zhu, Xiaodong Xi

Frontiers of Medicine 2018, Volume 12, Issue 3,   Pages 324-329 doi: 10.1007/s11684-017-0558-z

Abstract:

Splenic lymphoma with villous lymphocytes (SLVL) or splenic marginal zone lymphoma with circulatingIn this study, we report a case of B-lymphoproliferative disorder with villous lymphocytes harboringIn this report, we described an unusual case of B-lymphoproliferative disorder with villous lymphocytes14)(q24;q32) translocation, which could provide help in the diagnosis and differential diagnosis of B-lymphocytic

Keywords： splenic lymphoma with villous lymphocytes     splenic marginal zone lymphoma     transformation     chromosome translocation    

HTML PDF Collect

Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells

Sumedha Roy, Yuan Zhuang

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 374-386 doi: 10.1007/s11684-018-0652-x

Abstract: factors known as Id proteins, or inhibitor of DNA binding and differentiation, is capable of regulating cellcertain Id proteins are reported to act as tumor suppressors in the development of Burkitt’s lymphomain humans, and hepatosplenic and innate-like T cell lymphomas in mice.

Keywords： Id proteins     lymphoma     leukemia     T cells     B cells     tumor suppressor     oncogene    

HTML PDF Collect

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 747-757 doi: 10.1007/s11684-022-0954-x

Abstract: efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific Bcell response.Similarly, the responses of SARS-CoV-2 RBD-specific B cells and memory B cells were boosted by the secondor two doses), which enhanced neutralization against highly mutated SARS-CoV-2 variants and memory Bcell responses.

Keywords： COVID-19 convalescent     SARS-CoV-2     inactivated vaccination     neutralizing antibody     B cell response    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: However, for patients with relapsed or treatment-resistant lymphoma, a novel treatment approach is urgentlyBased on recent clinical data, approximately 50% of patients with relapsed or refractory B-cell lymphomaachieved complete remission after receiving the CD19 CAR-T cell therapy.cells, were studied under preclinical and clinical evaluations for use in the treatment of lymphoma.the toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Diffuse cystic lung diseases

Jay H. Ryu, Xinlun Tian, Misbah Baqir, Kaifeng Xu

Frontiers of Medicine 2013, Volume 7, Issue 3,   Pages 316-327 doi: 10.1007/s11684-013-0269-z

Abstract:

Diffuse cystic lung diseases are uncommon but can present a diagnostic challenge because increasing“Diffuse” distribution in the lung implies involvement of all lobes.Diffuse lung involvement with cystic lesions can be seen in pulmonary lymphangioleiomyomatosis, pulmonaryLangerhans’ cell histiocytosis, lymphoid interstitial pneumonia, Birt-Hogg-Dubé syndrome

Keywords： cyst     lung disease     interstitial lung disease     lymphangioleiomyomatosis     Langerhans’ cell histiocytosis     Birt-Hogg-Dubé    

HTML PDF Collect

Study of recombinant human IFN-α-2b bacilli Calmette–Guerin activated killer cells and against bladdercancer cell in vitro

FAN Xiaodong, HAN Ruifa

Frontiers of Medicine 2007, Volume 1, Issue 4,   Pages 377-380 doi: 10.1007/s11684-007-0073-8

Abstract: Recombinant IFN--2b-BCG, wild-type BCG (wBCG), wild-type BCG and IFN--2b were coincubated with PBMCs

Keywords： Urology     powerful     2b-BCG     Tianjin institute     wild-type    

HTML PDF Collect

characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 139-149 doi: 10.1007/s11684-021-0835-8

Abstract: The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients withrelapsed/refractory B-cell precursor acute lymphoblastic leukemia.and A-2019 are potent antitumor agents and capable of recruiting CD3 positive T cells, enhancing T-cellfunction, mediating B-cell depletion, and eventually inhibiting tumor growth in Raji xenograft models

Keywords： B-cell acute lymphoblastic leukemia     bispecific antibody     trispecific antibody     CD19     CD20    

HTML PDF Collect

Title Author Date Type Operation

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Journal Article

Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse largeB-cell lymphoma

Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao

Journal Article

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Journal Article

extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphomaafter chimeric antigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Muhammad Furqan,Yamei Chen,Akintunde Akinleye,Judy Sarungbam,Alan Gass,Karen Seiter,Delong Liu

Journal Article

Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2

Journal Article

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation

Xiaofeng Shi, Rong Ba, Haiyan You, Qian Jiang, Jiansong Huang, Jianhua Mao, Lanxiu Han, Shuo Zhang, Qin Zhuang, Xianqiu Yu, Lixia Wang, Yun Wang, Dongya Li, Wei Zhu, Yong Zhang, Yan Zhu, Xiaodong Xi

Journal Article

Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells

Sumedha Roy, Yuan Zhuang

Journal Article

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Diffuse cystic lung diseases

Jay H. Ryu, Xinlun Tian, Misbah Baqir, Kaifeng Xu

Journal Article

Study of recombinant human IFN-α-2b bacilli Calmette–Guerin activated killer cells and against bladdercancer cell in vitro

FAN Xiaodong, HAN Ruifa

Journal Article

characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell

Journal Article